Blogs may smooth ups, downs of breast cancer: study

Share this article:

Results from a study published in the Journal of Clinical Oncology suggest that creating a personal website, or blog, may help women with breast cancer to battle depression symptoms.

While having an outlet during a difficult time is thought to be therapeutic, this is the first randomized clinical trial to assess the actual benefit, wrote researchers from the University of California Los Angeles.

100 women—recruited from BreastLink, a network of cancer centers—were split into two groups. Half were enrolled in a workshop which gave them hands-on instruction in creating a site with WordPress. The other half were told they were wait-listed for the workshop. The women were assessed before they were randomized and six months after they split.

Six months in, the blogger group showed “significant benefit” in their depressive symptoms, life appreciation and a more positive mood, researchers said. However, there was no reported difference on the perceived strength of their relationships, the impact of negative moods or “intrusive thoughts.” The biggest change in mood was observed in patients currently undergoing therapy—compared to those who had completed treatment.

The study's lead author, Anette Stanton of UCLA, told Reuters Health that the websites were helpful for women to “be able to truly tell their story, express emotions and communicate with others without having to repeat information about their diagnosis and treatment.”

Results were “encouraging,” said co-author James Waisman, as reported by Reuters, adding that “it's a small sample size and...needs to be confirmed and reproduced.”

The National Cancer Institute estimates that as many as a quarter of cancer patients suffer from depression.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...